Lumy Biosciences, recently announced the completion of a Pre-A round financing of nearly 100 million RMB. The funds raised will be used to advance and expand the company's next-generation product pipeline, establish a carbon-negative synthesis base, and develop the talent team.
Founded in 2021, Lumy Biosciences is an innovative synthetic biology company focused on light-driven CO2 recycling. They utilize photosynthetic autotrophic microorganisms, specifically cyanobacteria, as a chassis and employ rational design and multidimensional editing to reshape metabolism, creating nearly a hundred "carbon-negative" cell factories. These factories enable the direct utilization of solar energy and carbon dioxide for the targeted synthesis of various platform compounds and natural products.
Synthetic biology involves modifying microorganisms such as E. coli and yeast to produce a wide range of chemicals, serving as an alternative technology to traditional chemical processes in sectors such as food, chemical, pharmaceutical, and materials. However, most current synthetic biology techniques rely on sugar fermentation as the microbial chassis, resulting in high raw material costs and unavoidable greenhouse gas emissions during production. In contrast, Lumy Biosciences develops light-driven synthetic biology technology to "manufacture compounds from air and reshape the world through carbon recycling," assisting the biomanufacturing industry in transitioning from carbon reduction to carbon negativity and achieving true carbon absorption.
Lumy Biosciences' core R&D team has accumulated over a decade of technical expertise in photosynthetic organism modification, artificial photosynthetic microbial community development, and metabolic modeling. They have patented several technologies in the field of light-driven synthetic biology. The company has developed novel underlying technologies, including the DTL-B metabolic optimization platform based on cofactor self-circulation in cell-free systems, the DeepMARS pathway acceleration system, and the flexible reconstruction of photosynthetic electron transport/carbon fixation. These technologies enable rapid strain development and improved synthesis efficiency.
Building upon their technical platform, Lumy Biosciences has established a leading global library of photosynthetic cell factories, enabling the directed manufacturing of pharmaceutical ingredients, chemical raw materials, and biodegradable materials using carbon dioxide. This significantly reduces costs. Currently, Lumy Biosciences focuses on functional active ingredients, health nutrition, and sustainable agriculture. They have achieved an ecological closed-loop from research and development to application in the light-driven synthetic biology platform and have established multiple business pipelines, including cyanidin, colchicine, and demethoxycurcumin. Lumy Biosciences adheres to the unique "carbon-negative production mode" aligned with the national carbon neutrality policies and future manufacturing trends. They have signed commercial cooperation agreements with several industry leaders and are expected to collaborate with them to launch various products in the coming years, promoting inorganic raw materials and reducing carbon footprint.
Disclaimer: Despite our efforts to maintain accuracy, errors are unavoidable due to our limited expertise. Some information may not be up to date, and we welcome your feedback to make necessary corrections. This document is intended solely for the purpose of providing a business-oriented and written introduction to the field of synthetic biology. It does not constitute any investment advice. We appreciate your understanding.